Sickle Cell Disease |
Dr. De-Fu Zeng |
City of Hope, Beckman Research Institute |
Phase 1 |
Active, not recruiting |
3 |
|
HIV/AIDS |
Prof. John A. Zaia |
City of Hope, Beckman Research Institute |
Phase 1 |
Active, not recruiting |
12 |
|
COVID-19 Respiratory Disorders |
Prof. John A. Zaia |
City of Hope, Beckman Research Institute |
Phase 1 |
Launching |
N/A |
|
Bladder or Urinary Tract Disorder |
James Yoo |
Wake Forest University Health Sciences |
Phase 1 |
Not yet recruiting |
10 |
|
Heart failure |
Dr. Joseph C. Wu |
Stanford University |
Phase 1 |
Recruiting |
18 |
|
Leukemia, Acute Myeloid (AML) |
Joseph Paul Woodard |
Immune-Onc Therapeutics |
Phase 1 |
Recruiting |
106 |
|
Parkinson's Disease |
Dr. Edward Wirth III |
Aspen Neuroscience |
Phase 1 |
Launching |
N/A |
|
Sickle Cell Disease |
David Williams |
Boston Children’s Hospital |
Phase 2 |
Recruiting |
25 |
|
Huntington's Disease |
Dr. Vicki Wheelock |
University of California, Davis |
Phase 1/2 |
Completed |
29 |
|
Blood Cancer Solid Tumors |
Professor Irving L Weissman MD |
Stanford University |
Phase 1 |
Completed |
88 |
|
Solid Tumors |
Pei Wang |
Eureka Therapeutics, Inc. |
Phase 1/2 |
Launching |
N/A |
|
Brain Cancer |
Dr. Leo D Wang |
City of Hope, Beckman Research Institute |
Phase 1 |
Recruiting |
18 |
|
Sickle Cell Disease |
Mark C. Walters M.D. |
University of California, San Francisco |
Phase 1 |
Not yet recruiting |
9 |
|
COVID-19 Respiratory Disorders |
William van der Touw |
Celularity Inc. |
Phase 1/2 |
Unknown status |
86 |
|
Lupus, Systemic Lupus Erythematosus (SLE) |
Bob Valamehr |
Fate Therapeutics, Inc. |
Phase 1 |
Launching |
N/A |
|
Brain Cancer |
Dr. Reena Parada Thomas |
Stanford University |
Phase 1 |
Launching |
N/A |
|
HIV/AIDS |
Geoff Symonds |
Calimmune, Inc. |
Phase 1/2 |
Completed |
13 |
|
Amyotrophic Lateral Sclerosis |
Professor Clive Niels Svendsen |
Cedars-Sinai Medical Center |
Phase 1/2 |
Completed |
18 |
|
Retinitis Pigmentosa |
Clive Svendsen |
Cedars-Sinai Medical Center |
Phase 1 |
Recruiting |
16 |
|
Amyotrophic Lateral Sclerosis |
Clive Svendsen |
Cedars-Sinai Medical Center |
Phase 1 |
Launching |
N/A |
|
Type 1 diabetes |
Peter Stock |
University of California, San Francisco |
Phase 1/2 |
Recruiting |
8 |
|
Age-related macular degeneration |
Dr. Jeffrey H Stern |
Luxa Biotechnology |
Phase 1/2 |
Launching |
N/A |
|
Stroke |
Dr. Gary Steinberg |
Stanford University |
Phase 1 |
Recruiting |
30 |
|
Heart failure |
Dr. Rachel Ruckdeschel Smith |
Capricor, Inc |
Phase 2 |
Closed |
135 |
|
Solid Tumors |
Dr. Dennis J Slamon |
University of California, Los Angeles |
Phase 1 |
Completed |
46 |
|
Type 1 diabetes |
Dr. William Sietsema |
Caladrius Biosciences |
Phase 2 |
Completed |
113 |
|
Danon Disease Pediatrics |
Dr. Jonathan Schwartz |
Rocket Pharmaceuticals, Inc. |
Phase 2 |
Launching |
N/A |
|
Melanoma Skin cancer |
Dr. Antoni Ribas MD/PhD |
University of California, Los Angeles |
Phase 1 |
Closed |
5 |
|
Bone or Cartilage Disease |
Dr. Gayatri Rao |
Rocket Pharmaceuticals, Inc. |
Phase 1 |
Closed |
1 |
|
Blood Disorders |
Ilya Rachman MD PhD |
Nexcella, Inc. |
Phase 1 |
Launching |
N/A |
|
Blood Cancer Bone Marrow Transplant and Viral Infection |
Michael A. Pulsipher |
Children’s Hospital of Los Angeles |
Phase 1/2 |
Active, not recruiting |
60 |
|
Brain Cancer Breast Cancer |
Dr Saul J Priceman |
City of Hope, Beckman Research Institute |
Phase 1 |
Recruiting |
39 |
|
Brain Cancer |
Dr Jana Portnow |
City of Hope, Beckman Research Institute |
Phase 1 |
Launching |
N/A |
|
B cell cancers Leukemia Leukemia, Acute Myeloid (AML) |
Dr. Matthew H Porteus |
Stanford University |
Phase 1 |
Recruiting |
22 |
|
Anemia |
Dr. Matthew H Porteus |
Stanford University |
Phase 1/2 |
Launching |
N/A |
|
Immune Disease Leukocyte Adhesion Deficiency |
Dr. Kinnari Patel |
Rocket Pharmaceuticals, Inc. |
Phase 1/2 |
Completed |
9 |
|
Immune Disease Pediatrics Severe Combined Immunodeficiency, X-linked (X-SCID) |
Dr. Judith A Shizuru Wendy Pang |
Stanford University Jasper Therapeutics, Inc. |
Phase 1/2 |
Recruiting |
40 |
|
Brain Cancer |
Dr. Hideho Okada |
University of California, San Francisco |
Phase 1 |
Launching |
N/A |
|
Sarcoma |
Theodore Scott Nowicki |
University of California, Los Angeles |
Phase 1 |
Closed |
5 |
|
Epilepsy |
Dr. Cory R Nicholas |
Neurona Therapeutics |
Phase 1 |
Recruiting |
40 |
|
Stroke |
Dr. Bijan Nejadnik |
SanBio, Inc. |
Phase 2 |
Completed |
163 |
|
Anemia |
Ryotaro Nakamura |
City of Hope, Beckman Research Institute |
Phase 1 |
Launching |
N/A |
|
B cell cancers Leukemia |
Dr. David B. Miklos |
Stanford University |
Phase 1 |
Active, not recruiting |
56 |
|
Kidney Failure |
Dr. Everett H. Meyer |
Stanford University |
Phase 1 |
Recruiting |
22 |
|
COVID-19 |
Dr. Michael Matthay MD |
University of California, San Francisco |
Phase 2 |
Completed |
120 |
|
Heart disease associated with Duchenne muscular dystrophy |
Dr. Linda Marban |
Capricor, Inc |
Phase 2 |
Completed |
25 |
|
Alpha Thalassemia Major |
Dr. Tippi C. MacKenzie MD |
University of California, San Francisco |
Phase 1 |
Enrolling by invitation |
10 |
|
Brain Cancer |
Crystal Mackall |
Stanford University |
Phase 1 |
Recruiting |
54 |
|
Kidney Failure |
Dr Robert Lowsky |
Stanford University |
Phase 1 |
Active, not recruiting |
15 |
|
Pulmonary Hypertension Vascular Disease |
Dr. Michael I Lewis |
Cedars-Sinai Medical Center |
Phase 1/2 |
Completed |
26 |
|
Spinal Cord Injury |
Dr. Jane Stephanie Lebkowski Dr. |
Geron Corporation |
Phase 1 |
Completed |
5 |
|
Age-related macular degeneration |
Dr Jane S Lebkowski |
Regenerative Patch Technologies LLC |
Phase 2 |
Launching |
N/A |
|
Solid Tumors |
Dr. John Le Gall |
Allogene Therapeutics |
Phase 1 |
Launching |
N/A |
|
Kidney Failure |
Jeffrey Lawson |
Humacyte, Inc. |
Phase 3 |
Active, not recruiting |
240 |
|
Kidney Failure |
Jeffrey Lawson |
Humacyte, Inc. |
Phase 3 |
Completed |
355 |
|
Osteonecrosis |
Nancy E. Lane |
University of California, Davis |
Phase 1/2 |
Completed |
58 |
|
Genetic Disorder Immune Disease Pediatrics Severe Combined Immunodeficiency, Adenosine deaminase-deficient (ADA-SCID) |
Dr. Donald B Kohn Leslie Meltzer Dr. Donald B. Kohn PhD |
University of California, Los Angeles Orchard Therapeutics plc |
Phase 2 |
Completed |
10 |
|
Immune Disease Pediatrics X-linked Chronic Granulomatous Disease |
Dr. Donald B. Kohn PhD |
University of California, Los Angeles |
Phase 1/2 |
Recruiting |
16 |
|
Pediatrics Sickle Cell Disease |
Dr. Donald B. Kohn PhD |
University of California, Los Angeles |
Phase 1 |
Active, not recruiting |
4 |
|
Retinitis Pigmentosa |
Dr. Henry John Klassen |
University of California, Irvine |
Phase 1/2 |
Completed |
28 |
|
Retinitis Pigmentosa |
Henry John Klassen |
jCyte, Inc |
Phase 2 |
Completed |
84 |
|
Retinitis Pigmentosa |
Henry John Klassen |
jCyte, Inc |
Phase 2 |
Completed |
84 |
|
B cell cancers Leukemia |
Thomas J Kipps |
University of California, San Diego |
Phase 1/2 |
Active, not recruiting |
102 |
|
Blood Cancer |
Thomas J Kipps |
University of California, San Diego |
Phase 1 |
Completed |
26 |
|
Colon Cancer |
Ivan King |
Tachyon Therapeutics, Inc |
Phase 1 |
Launching |
N/A |
|
Neurological Disorders Other |
Prof. Olivia Kim-McManus |
University of California, San Diego |
Phase 1/2 |
Launching |
N/A |
|
Amyotrophic Lateral Sclerosis |
Dr. Ralph Kern |
BrainStorm Cell Therapeutics |
Phase 3 |
Completed |
196 |
|
HIV/AIDS |
William Kennedy |
Excision BioTherapeutics |
Phase 1 |
Active, not recruiting |
6 |
|
Blood Cancer |
Dr. Edward Kavalerchik |
Angiocrine Bioscience, Inc. |
Phase 1 |
Completed |
10 |
|
Blood Cancer |
Dr. Edward Kavalerchik |
Angiocrine Bioscience, Inc. |
Phase 1/2 |
Completed |
42 |
|
Brain Cancer |
Noriyuki Kasahara |
University of California, San Francisco |
Phase 1 |
Launching |
N/A |
|
Melanoma |
Anusha Kalbasi |
Stanford University |
Phase 1 |
Launching |
N/A |
|
Arthritis Osteoarthritis |
Dr. Kristen A Johnson |
Calibr |
Phase 1 |
Completed |
60 |
|
Type 1 diabetes |
Manasi Jaiman |
ViaCyte, Inc. |
Phase 1/2 |
Completed |
49 |
|
Age-related macular degeneration |
Dr. Mark S Humayun |
University of Southern California |
Phase 1 |
Unknown status |
16 |
|
Bone or Cartilage Disease Hearing Loss Intellectual Disability Metabolic Disorders Vision Loss |
Dr Robert Hayes |
Immusoft Corporation |
Phase 1 |
Launching |
N/A |
|
Brain Cancer |
Anthony J. Gringeri |
ImmunoCellular Therapeutics |
Phase 3 |
Suspended |
234 |
|
Immune Disease Severe Combined Immunodeficiency, X-linked (X-SCID) |
Stephen Gottschalk |
St. Jude Children’s Research Hospital |
Phase 1/2 |
Suspended |
28 |
|
Type 1 diabetes |
Howard Foyt |
ViaCyte, Inc. |
Phase 1/2 |
Closed |
19 |
|
B cell cancers |
Dr. Paul Finnegan |
Angiocrine Bioscience, Inc. |
Phase 3 |
Closed |
130 |
|
Developmental Disorders Spina Bifida |
Dr. Diana L. Farmer |
University of California, Davis |
Phase 2 |
Recruiting |
55 |
|
Neurological Disorders |
Amit Etkin |
Alto Neuroscience |
Phase 2 |
Launching |
N/A |
|
Leukemia, Acute Myeloid (AML) |
Rochelle Emery |
Senti Biosciences, Inc. |
Phase 1 |
Launching |
N/A |
|
Lung Cancer |
Dr. Steven M. Dubinett MD |
University of California, Los Angeles |
Phase 1 |
Active, not recruiting |
24 |
|
Melanoma |
Robert Dillman |
Caladrius Biosciences |
Phase 3 |
Closed |
4 |
|
Corneal Damage |
Dr. Sophie X Deng |
University of California, Los Angeles |
Phase 1 |
Recruiting |
20 |
|
Leukemia, Acute Myeloid (AML) |
Dr. Colleen Delaney |
Nohla Therapeutics Inc |
Phase 2 |
Closed |
146 |
|
HIV/AIDS Immune Disease |
Steven G. Deeks |
University of California, San Francisco |
Phase 1/2 |
Recruiting |
18 |
|
Severe Combined Immunodeficiency, Artemis deficient (ART-SCID) |
Mort Cowan |
University of California, San Francisco |
Phase 1 |
Recruiting |
25 |
|
Solid Tumors |
Dr. Pamela Reilly Contag |
BioEclipse Therapeutics INC. |
Phase 1 |
Recruiting |
60 |
|
Beta Thalassemia |
Bettina Cockroft |
Sangamo BioSciences, Inc. |
Phase 1/2 |
Completed |
5 |
|
Cystinosis Kidney Failure |
Dr. Stephanie Cherqui |
University of California, San Diego |
Phase 1/2 |
Active, not recruiting |
6 |
|
Leukemia, Acute Myeloid (AML) |
Mark Chao |
Forty Seven Inc. |
Phase 1 |
Closed |
258 |
|
Colon Cancer |
Mark Chao |
Forty Seven Inc. |
Phase 1/2 |
Completed |
78 |
|
Osteoarthritis |
Dr. Thomas W Chalberg Jr. |
Genascence Corporation |
Phase 1 |
Launching |
N/A |
|
Sickle Cell Disease |
Dr Pierre Caudrelier |
ExCellThera Inc. |
Phase 1 |
Withdrawn |
N/A |
|
HIV/AIDS |
Dr. Angelo Manuel Almeida Cardoso Ph.D., MD |
City of Hope, Beckman Research Institute |
Phase 1 |
Launching |
N/A |
|
Leukemia, Acute Myeloid (AML) |
Elizabeth Budde |
City of Hope, Beckman Research Institute |
Phase 1 |
Launching |
N/A |
|
Brain Cancer |
Dr. Christine E. Brown |
City of Hope, Beckman Research Institute |
Phase 1 |
Active, not recruiting |
82 |
|
Kidney Failure |
Daniel Brennan |
Medeor Acquisition Corp. |
Phase 3 |
Completed |
30 |
|
Corneal Damage |
R. Kim Brazzell |
Combangio, Inc. |
Phase 2 |
Launching |
N/A |
|
Spinal Cord Injury |
Francois Binette |
Lineage Cell Therapeutics, Inc. |
Phase 1/2 |
Completed |
25 |
|
Anemia Bone Marrow Transplant and Viral Infection |
Alice Bertaina |
Stanford University |
Phase 1/2 |
Launching |
N/A |
|
Immune Disease |
DR Jonathan Benjamin |
ImmPACT-Bio, Inc. |
Phase 1/2 |
Launching |
N/A |
|
Multiple Myeloma |
Rajesh Belani MD |
Poseida Therapeutics, Inc. |
Phase 1 |
Closed |
105 |
|
Muscle Injury |
Peter C Belafsky |
University of California, Davis |
Phase 1/2 |
Recruiting |
62 |
|
Parkinson's Disease |
Krystof S. Bankiewicz |
Brain Neurotherapy Bio |
Phase 1 |
Active, not recruiting |
11 |
|
IPEX Syndrome |
Dr. Rosa Bacchetta |
Stanford University |
Phase 1 |
Recruiting |
30 |
|
HIV-related Lymphoma HIV/AIDS |
Dr Mehrdad Abedi |
University of California, Davis |
Phase 1/2 |
Active, not recruiting |
11 |
|